DRC is supporting the development of a new oral treatment for ulcerative (UC) and is currently seeking sites interested in participating in Phase 3 clinical studies intended to evaluate safety and efficacy in patients with moderately to severely active UC.
Patients may be able to take part in the clinical program if they*:
· Are 16 to 80 years of age
· Were diagnosed with moderate to severe ulcerative colitis at least 3 months ago
· Did not respond to, are no longer responding to, or did not tolerate another UC therapy
A Non-erosive Gastroesophageal Reflux Disease (GERD) study to evaluate the safety and efficacy of the investigational product (IP) in pediatric patients (age 2-11 years) with symptomatic non erosive gastroeosophageal reflux disease (GERD). The study will consist of 2 periods – screening (up to 28 days) and treatment (12 weeks). Recruitment is expected to start in the first half of 2020 and is expected to last for approximately 2 years.
A multicenter, randomized, Double-blind, Placebo-controlled Induction Study of the Efficacy and safety of Study Drug in subjects with moderately to Severely Active Crohn's disease
The Phase 3 clinical development program is designed to evaluate the safety and efficacy of mirikizumab in patients with moderate to severely active ulceration colitis